CLINICAL_TRIALS
trial_result
· 2020-09-16
Clinical Trial Update: A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel [Phase 1, Phase 2]
Summary
Phase 1/2 study of CS7017, an oral PPARγ agonist, in combination with paclitaxel for Anaplastic Thyroid Cancer; study terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Daiichi Sankyo | Conditions: Anaplastic Thyroid Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-09-16